Jiangxi Shanxing Biotechnology Co., Ltd.

Jiangxi Shanxing Biotechnology Co., Ltd. is a biotechnology company founded by Mr. Wang Jingsu, one of the original founders of China Medical City in Taizhou, dedicated to the integration and development of new medical technologies related to gut microbiota. In 2018, Shanxing was successively selected for Jiangxi Province's first batch of "Double Thousand Plan" high-level entrepreneurial team introduction projects and Nanchang City's "Hongcheng Plan" talent project.
Shanxing's "Gut Microbiota Industrialization" project applies gut microbiota screened and collected from healthy individuals to clinical treatment. This project is widely used in the treatment of diseases of the immune, metabolic, endocrine, and nervous systems, and has achieved excellent therapeutic results in the treatment of over 50 diseases including severe infections, tumors, autism, functional constipation, and diarrhea. At present, Shanxing has established clinical cooperation within Jiangxi Province with the First Affiliated Hospital of Nanchang University, Jiangxi Cancer Hospital, Nanchang Ninth Hospital, and the 334 Hospital Affiliated to Nanchang University, successfully curing multiple cases including "gastrointestinal graft-versus-host disease after hematopoietic stem cell transplantation," "recurrent constipation for over 10 years," and "persistent diarrhea for over half a year."
The company's founder, Mr. Wang Jingsu, has been appointed as a *** professor at the Health Research Institute of Fudan University, director of the Gut Microbiota Homeostasis Laboratory at the University of Science and Technology of China, and director and visiting professor of the Joint Laboratory of Immunology and Microecology at the Institute of Biomedical Translational Research of Jinan University. The team led by Mr. Wang Jingsu has successively established China's * GMP-compliant gut microbiota preparation center and built China's *** "stool bank"; formulated a standardized healthy population screening technical protocol compliant with US FDA standards, pioneered the * dual-pathway gut microbiota preparation technology, and organized China's first large-scale gut microbiota metagenomic sequencing and screening of healthy populations, among other industry ***.
Shanxing will establish Jiangxi Ganzhou Shanxing Biotechnology Co., Ltd. in Ganzhou City, carrying out screening of healthy populations and preparation of healthy microbiota banks in the region, and initiating multiple efforts including metagenomic sequencing and screening of gut microbiota in healthy populations in Ganzhou, collection of healthy gut microbiota donors, construction of Jiangxi's * gut microbiota sample bank (stool bank), and clinical research and application of gut microbiota.